RESUMEN

The anticancer drug Cancerolysin has been developed, by using the mutant Adel2 variant of human adenovirus serotype 5 designed at the State Research Center of Virology and Biotechnology. Cancerolysin possesses a high degree of replication activity for complementary cells 293 and p53-deficient tumor cells and, at the same time, has significant replication limitations in normal human cells. Preclinical studies of the drug on laboratory animals (mice, rabbits, guinea pigs) have demonstrated its harmlessness and safety. When stored at -40 and -70 degrees C, the drug showed no significant activity throughout the control observational period (1 year).

Asunto(s)

Adenoviridae , Antineoplásicos , Efecto Citopatogénico Viral , Viroterapia Oncolítica , Adenoviridae/genética , Anafilaxia , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/inmunología , Antineoplásicos/toxicidad , Línea Celular Transformada , Línea Celular Tumoral , Cobayas , Humanos , Terapia de Inmunosupresión , Inyecciones Intraperitoneales , Inyecciones Subcutáneas , Macrófagos Peritoneales/inmunología , Ratones , Ratones Endogámicos BALB C , Fagocitosis , Conejos , Replicación Viral